ArticleAbdominal radiology (New York)2026
Quantification of hepatic steatosis on post-contrast computed tomography scans using artificial intelligence tools.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- CT Attenuation Thresholds for Grading Hepatic Steatosis in Adults with Overweight or Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeEarly detection of steatotic liver disease (SLD) is critically important. In clinical practice, hepatic steatosis is frequently diagnosed using computed tomography (CT) performed for unrelated clinical indications. An equation for estimating magnetic resonance proton density fat fraction (MR-PDFF) using liver attenuation on non-contrast CT exists, but no equivalent equation exists for post-contrast CT. We sought to (1) determine whether an automated workflow can accurately measure liver attenuation, (2) validate previously identified optimal thresholds for liver or liver-spleen attenuation in post-contrast studies, and (3) develop a method for estimating MR-PDFF (FF) on post-contrast CT.
methodsThe fully automated TotalSegmentator 'total' machine learning model was used to segment 3D liver and spleen from non-contrast and post-contrast CT scans. Mean attenuation was extracted from liver (L) and spleen (S) volumes and from manually placed regions of interest (ROIs) in multi-phase CT scans of two cohorts: derivation (n = 1740) and external validation (n = 1044). Non-linear regression was used to determine the optimal coefficients for three phase-specific (arterial, venous, delayed) increasing exponential decay equations relating post-contrast L to non-contrast L. MR-PDFF was estimated from non-contrast CT and used as the reference standard.
resultsThe mean attenuation for manual ROIs versus automated volumes were nearly perfectly correlated for both liver and spleen (r > .96, p < .001). For moderate-to-severe steatosis (L < 40 HU), the density of the liver (L) alone was a better classifier than either liver-spleen difference (L-S) or ratio (L/S) on post-contrast CTs. Fat fraction calculated using a corrected post-contrast liver attenuation measure agreed with non-contrast FF > 15% in both the derivation and external validation cohort, with AUROC between 0.92 and 0.97 on arterial, venous, and delayed phases.
conclusionAutomated volumetric mean attenuation of liver and spleen can be used instead of manually placed ROIs for liver fat assessments. Liver attenuation alone in post-contrast phases can be used to assess the presence of moderate-to-severe hepatic steatosis. Correction equations for liver attenuation on post-contrast phase CT scans enable reasonable quantification of liver steatosis, providing potential opportunities for utilizing clinical scans to develop large scale screening or studies in SLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.